| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 2 | +100.00% | +5.67% | +1.43% | +4.25% | +4.25% | — |
| 14d | 2 | +100.00% | +0.81% | +1.83% | -1.02% | -1.02% | — |
| 30d | 2 | +100.00% | -5.01% | -1.55% | -3.46% | -3.46% | — |
| 60d | 2 | +100.00% | +9.05% | +6.95% | +2.10% | +2.10% | — |
| 90d | 2 | +100.00% | -3.77% | +11.58% | -15.35% | -15.35% | — |
| 180d | 2(1 pending) | +100.00% | +96.38% | +26.89% | +69.50% | +69.50% | — |
| 1y | 2(1 pending) | +100.00% | +175.72% | +52.18% | +123.55% | +123.55% | — |
| 2y | 2(1 pending) | +100.00% | +182.69% | +65.56% | +117.14% | +117.14% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| KROS KEROS THERAPEUTICS, INC. | PURCHASE CHIEF EXECUTIVE OFFICER | 55,000 | $0.30 | $16.5K | 440,708 | Apr 2, 2026 | Apr 6, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE CHIEF EXECUTIVE OFFICER | 55,000 | — | — | 197,444 | Apr 2, 2026 | Apr 6, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 217,000 | — | — | 217,000 | Feb 24, 2026 | Feb 26, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 100,000 | — | — | 100,000 | Feb 24, 2026 | Feb 26, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE CHIEF EXECUTIVE OFFICER | 7,015 | $16.17 | $113.4K | 385,708 | Feb 19, 2026 | Feb 20, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 62,500 | — | — | 62,500 | Jan 7, 2026 | Jan 9, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 90,500 | — | — | 392,723 | Sep 3, 2025 | Sep 5, 2025 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE CHIEF EXECUTIVE OFFICER | 49,367 | — | — | 252,444 | Apr 4, 2025 | Apr 7, 2025 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE CHIEF EXECUTIVE OFFICER | 49,367 | $0.30 | $14.8K | 302,223 | Apr 4, 2025 | Apr 7, 2025 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 125,000 | — | — | 125,000 | Feb 23, 2024 | Feb 23, 2024 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 125,000 | — | — | 125,000 | Feb 13, 2024 | Feb 15, 2024 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE Chief Executive Officer | 4,000 | — | — | 45,087 | Apr 8, 2023 | Apr 11, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE Chief Executive Officer | 4,000 | $0.48 | $1.9K | 252,856 | Apr 8, 2023 | Apr 11, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 200,000 | — | — | 200,000 | Feb 16, 2023 | Feb 17, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE Chief Executive Officer | 5,000 | $0.30 | $1.5K | 248,856 | Jun 9, 2022 | Jun 10, 2022 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE Chief Executive Officer | 5,000 | — | — | 8,822 | Jun 9, 2022 | Jun 10, 2022 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 165,000 | — | — | 165,000 | Jan 21, 2022 | Jan 25, 2022 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 127,200 | — | — | 127,200 | Jan 10, 2021 | Jan 12, 2021 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE Chief Executive Officer | 20,000 | $16.00 | $320.0K | 243,856 | Apr 13, 2020 | Apr 13, 2020 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE Chief Executive Officer | 11,169 | — | — | 0 | Apr 13, 2020 | Apr 13, 2020 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE Chief Executive Officer | 11,169 | — | — | 223,856 | Apr 13, 2020 | Apr 13, 2020 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 696,569 | — | — | 696,569 | Apr 7, 2020 | Apr 8, 2020 ↗ | View → |